Pontus Eriksson

This study identifies CD44v6 as a driver of bladder cancer aggressiveness and chemoresistance, linking its expression to poor patient outcomes and therapeutic resistance.

The paper uses biologically-informed machine learning to identify a new bladder cancer subgroup with NRF2 overactivity, which is clinically actionable and resistant to standard treatments.

This paper evaluates gene expression predictors of lymph node metastasis in bladder cancer using two large cohorts, finding that existing and newly trained models perform poorly in independent validation.

The paper develops and evaluates a classifier for urothelial carcinoma subtypes that is robust across different platforms and preprocessing methods.